Evidence map›Paper›PMID 25669663›Full record

ArticleThe oncologist2015

Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.

Carmelo Carlo-Stella, Francesca Ricci, Serena Dalto, Rita Mazza, Michele Malagola, Francesca Patriarca, Simonetta Viviani, Domenico Russo, Laura Giordano, Luca Castagna and 2 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Carmelo Carlo-StellaDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy carmelo.carlostella@cancercenter.humanitas.it.
Francesca RicciDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Serena DaltoDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Rita MazzaDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Michele MalagolaDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Francesca PatriarcaDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Simonetta VivianiDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Domenico RussoDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Laura GiordanoDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Luca CastagnaDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Paolo CorradiniDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Armando SantoroDepartment of Hematology and Oncology, Humanitas Cancer Center, and Biostatistical Unit, Humanitas Clinical and Research Center, Milan, Italy; Departments of Medical Biotechnology and Translational Medicine and Hematology, University of Milan, Milan, Italy; Hematology and BMT Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Hematology and BMT Unit, University of Brescia, Brescia, Italy; Hematology, Azienda Ospedaliera-Universitaria, Udine, Italy; Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Humanitas University · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITUniversity of Brescia · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBrentuximab vedotin (BV) has demonstrated an extraordinary efficacy in heavily pretreated classical Hodgkin lymphoma (cHL) patients, targeting CD30-positive cells; however, limited data have been reported on the efficacy of BV in cHL patients failing allogeneic stem cell transplantation (allo-SCT). The aim of this study was to retrospectively evaluate the efficacy and safety of BV in a multicenter setting of cHL relapsing or progressing after allo-SCT.

methodsSixteen BV-naïve patients with recurrent cHL after allo-SCT were included in a compassionate use program and treated with intravenous BV at the dose of 1.8 mg/kg of body weight every 3 weeks for a maximum of 16 cycles.

resultsThe objective response rate was 69%. Five patients (31%) had complete remission, and 6 (37%) had partial remission. Stable disease was observed in 4 patients (25%), and progressive disease was observed in 1 (6%). After median follow-up of 26 months (range: 5-30 months), median progression-free survival (PFS), overall survival (OS), and duration of response were 7, 25, and 5 months, respectively. The 2-year PFS and OS were 20% and 61%, respectively. Grade 3-4 hematological adverse events included anemia (15%), thrombocytopenia (12%), and neutropenia (18%). Grade 3 peripheral sensory neuropathy occurred in 2 patients (12%).

conclusionBV therapy is an effective and safe approach for achieving transient disease control in cHL patients with failed allo-SCT. To improve disease control, future studies should explore the combination of BV with targeted agents.

Indexed as

AdultBrentuximab VedotinDisease ProgressionFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansImmunoconjugatesItalyMalePrognosisRetrospective StudiesTreatment FailureTreatment OutcomeBrentuximab VedotinImmunoconjugatesAllogeneic stem cell transplantationBrentuximab vedotinCD30Relapsed or refractory Hodgkin lymphomaTargeted therapy

Identifiers

PMID25669663
PMCPMC4350807
OpenAlexW2101399073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.